{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T15:18:55Z","timestamp":1783178335491,"version":"3.54.6"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"NeuraLight LTD"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Med"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40290-026-00612-2","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T07:29:55Z","timestamp":1780126195000},"page":"299-309","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Changes in Saccadic Hypometria over Time to Monitor Parkinson\u2019s Disease Progression"],"prefix":"10.1007","volume":"40","author":[{"given":"Edmund","family":"Ben-Ami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eitan","family":"Raveh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eran","family":"Harpaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igal","family":"Riklin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tali","family":"Band","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Gurevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy N.","family":"Alcalay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Mir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle H. S.","family":"Tosin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher G.","family":"Goetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1410-6397","authenticated-orcid":false,"given":"Olivier","family":"Rascol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,30]]},"reference":[{"key":"612_CR1","doi-asserted-by":"publisher","first-page":"S106","DOI":"10.1016\/j.parkreldis.2015.09.048","volume":"22","author":"M Delenclos","year":"2016","unstructured":"Delenclos M, Jones DR, McLean PJ, Uitti RJ. Biomarkers in Parkinson\u2019s disease: advances and strategies. Parkinsonism Relat Disord. 2016;22:S106\u201310. https:\/\/doi.org\/10.1016\/j.parkreldis.2015.09.048.","journal-title":"Parkinsonism Relat Disord"},{"key":"612_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252212379","volume":"25","author":"R Arya","year":"2024","unstructured":"Arya R, Haque AKMA, Shakya H, Billah MdM., Parvin A, Rahman M-M, et al. Parkinson\u2019s disease: biomarkers for diagnosis and disease progression. Int J Mol Sci. 2024;25:12379. https:\/\/doi.org\/10.3390\/ijms252212379.","journal-title":"Int J Mol Sci"},{"key":"612_CR3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2147\/EB.S384763","volume":"15","author":"YR Sun","year":"2023","unstructured":"Sun YR, Beylergil SB, Gupta P, Ghasia FF, Shaikh AG. Monitoring eye movement in patients with Parkinson\u2019s Disease: what can it tell us? EB. 2023;15:101\u201312. https:\/\/doi.org\/10.2147\/EB.S384763.","journal-title":"EB"},{"key":"612_CR4","doi-asserted-by":"publisher","first-page":"105791","DOI":"10.1016\/j.parkreldis.2023.105791","volume":"115","author":"H Li","year":"2023","unstructured":"Li H, Zhang X, Yang Y, Xie A. Abnormal eye movements in Parkinson\u2019s disease: from experimental study to clinical application. Parkinsonism Relat Disord. 2023;115:105791. https:\/\/doi.org\/10.1016\/j.parkreldis.2023.105791.","journal-title":"Parkinsonism Relat Disord"},{"key":"612_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.tins.2023.11.001","author":"CA Antoniades","year":"2023","unstructured":"Antoniades CA, Spering M. Eye movements in Parkinson\u2019s disease: from neurophysiological mechanisms to diagnostic tools. Trends Neurosci. 2023. https:\/\/doi.org\/10.1016\/j.tins.2023.11.001.","journal-title":"Trends Neurosci"},{"key":"612_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci15040362","volume":"15","author":"P Diotaiuti","year":"2025","unstructured":"Diotaiuti P, Marotta G, Di Siena F, Vitiello S, Di Prinzio F, Rodio A, et al. Eye tracking in Parkinson\u2019s Disease: a review of oculomotor markers and clinical applications. Brain Sci. 2025;15:362. https:\/\/doi.org\/10.3390\/brainsci15040362.","journal-title":"Brain Sci"},{"key":"612_CR7","doi-asserted-by":"publisher","first-page":"772","DOI":"10.2183\/pjab.93.049","volume":"93","author":"Y Terao","year":"2017","unstructured":"Terao Y, Fukuda H, Hikosaka O. What do eye movements tell us about patients with neurological disorders?\u2014an introduction to saccade recording in the clinical setting. Proc Jpn Acad Ser B Phys Biol Sci. 2017;93:772\u2013801. https:\/\/doi.org\/10.2183\/pjab.93.049.","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"612_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/bs.pbr.2019.05.001","author":"AG Shaikh","year":"2019","unstructured":"Shaikh AG, Ghasia FF. Saccades in Parkinson\u2019s disease: Hypometric, slow, and maladaptive. Progress Brain Res [Internet]. 2019. https:\/\/doi.org\/10.1016\/bs.pbr.2019.05.001.","journal-title":"Progress Brain Res [Internet]"},{"key":"612_CR9","doi-asserted-by":"publisher","first-page":"3338","DOI":"10.1016\/j.neuropsychologia.2012.09.025","volume":"50","author":"MR MacAskill","year":"2012","unstructured":"MacAskill MR, Graham CF, Pitcher TL, Myall DJ, Livingston L, Van Stockum S, et al. The influence of motor and cognitive impairment upon visually-guided saccades in Parkinson\u2019s disease. Neuropsychologia. 2012;50:3338\u201347. https:\/\/doi.org\/10.1016\/j.neuropsychologia.2012.09.025.","journal-title":"Neuropsychologia"},{"key":"612_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2017.00592","volume":"8","author":"E Pretegiani","year":"2017","unstructured":"Pretegiani E, Optican LM. Eye movements in Parkinson\u2019s Disease and inherited Parkinsonian syndromes. Front Neurol. 2017;8:592. https:\/\/doi.org\/10.3389\/fneur.2017.00592.","journal-title":"Front Neurol"},{"key":"612_CR11","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1159\/000514246","volume":"84","author":"M Kobayashi","year":"2021","unstructured":"Kobayashi M, Kuwabara S. The association of visually guided saccades and DAT-SPECT findings in Parkinson\u2019s Disease. Eur Neurol. 2021;84:110\u20138. https:\/\/doi.org\/10.1159\/000514246.","journal-title":"Eur Neurol"},{"key":"612_CR12","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1007\/s00702-023-02681-y","volume":"130","author":"J Reiner","year":"2023","unstructured":"Reiner J, Franken L, Raveh E, Rosset I, Kreitman R, Ben-Ami E, et al. Oculometric measures as a tool for assessment of clinical symptoms and severity of Parkinson\u2019s disease. J Neural Transm. 2023;130:1241\u20138. https:\/\/doi.org\/10.1007\/s00702-023-02681-y.","journal-title":"J Neural Transm"},{"key":"612_CR13","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/mds.28374","volume":"36","author":"J Waldthaler","year":"2021","unstructured":"Waldthaler J, Stock L, Sommerkorn J, Kr\u00fcger\u2010Zechlin C, Timmermann L. Antisaccade latency is sensitive to longitudinal change of motor and cognitive symptoms in Parkinson\u2019s Disease. Mov Disord. 2021;36:266\u20138. https:\/\/doi.org\/10.1002\/mds.28374.","journal-title":"Mov Disord"},{"key":"612_CR14","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcab242","volume":"3","author":"C Wong","year":"2021","unstructured":"Wong C, Stavrou M, Elliott E, Gregory JM, Leigh N, Pinto AA, et al. Clinical trials in amyotrophic lateral sclerosis: a systematic review and perspective. Brain Commun. 2021;3:fcab242. https:\/\/doi.org\/10.1093\/braincomms\/fcab242.","journal-title":"Brain Commun"},{"key":"612_CR15","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000206429","volume":"102","author":"S Levy","year":"2024","unstructured":"Levy S, Sand IK, Berkman O, Raveh E, Ben-Ami E, Kreitman R, et al. Correlations between traditional disability and oculometric measures in multiple sclerosis (P6-6.010). Neurology. 2024;102:6381. https:\/\/doi.org\/10.1212\/WNL.0000000000206429.","journal-title":"Neurology"},{"key":"612_CR16","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1080\/21678421.2024.2376732","volume":"25","author":"O Berkman","year":"2024","unstructured":"Berkman O, Raveh E, Harpaz E, Kreitman R, Ben-Ami E, Nechushtan E, et al. Changes in saccadic intrusions over time as an objective biomarker to follow ALS disease progression. Amyotroph Lateral Scler Frontotemporal Degener. 2024;25:760\u20136. https:\/\/doi.org\/10.1080\/21678421.2024.2376732.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"612_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2025.107389","volume":"134","author":"T Gurevich","year":"2025","unstructured":"Gurevich T, Ezra A, Harpaz E, Ben-Ami E, Raveh E, Rascol O. Monitoring Parkinson\u2019s progression: eye movements vs. MDS-UPDRS III. Parkinsonism Relat Disord. 2025;134:107389. https:\/\/doi.org\/10.1016\/j.parkreldis.2025.107389.","journal-title":"Parkinsonism Relat Disord"},{"key":"612_CR18","unstructured":"Tosin M, Goetz C, Armstrong R, Januario C, Balint B, Mir P. Evaluating cognitive status in Parkinson\u2019s disease using a software-based eye-tracking platform: preliminary results of the PALOMA clinical trial. [abstract 230]. Mov Disord. 2024;39(suppl 1)."},{"key":"612_CR19","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1002\/mds.26134","volume":"30","author":"CA Antoniades","year":"2015","unstructured":"Antoniades CA, Demeyere N, Kennard C, Humphreys GW, Hu MT. Antisaccades and executive dysfunction in early drug\u2010naive Parkinson\u2019s disease: the discovery study. Mov Disord. 2015;30:843\u20137. https:\/\/doi.org\/10.1002\/mds.26134.","journal-title":"Mov Disord"},{"key":"612_CR20","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/j.1469-8986.2006.00403.x","volume":"43","author":"SB Hutton","year":"2006","unstructured":"Hutton SB, Ettinger U. The antisaccade task as a research tool in psychopathology: a critical review. Psychophysiology. 2006;43:302\u201313. https:\/\/doi.org\/10.1111\/j.1469-8986.2006.00403.x.","journal-title":"Psychophysiology"},{"key":"612_CR21","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1093\/brain\/awh035","volume":"127","author":"RJ Leigh","year":"2004","unstructured":"Leigh RJ, Kennard C. Using saccades as a research tool in the clinical neurosciences. Brain. 2004;127:460\u201377. https:\/\/doi.org\/10.1093\/brain\/awh035.","journal-title":"Brain"},{"key":"612_CR22","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/ana.410040405","volume":"4","author":"LA Abel","year":"1978","unstructured":"Abel LA, Schmidt D, Dell\u2019Osso LF, Daroff RB. Saccadic system plasticity in humans. Ann Neurol. 1978;4:313\u20138. https:\/\/doi.org\/10.1002\/ana.410040405.","journal-title":"Ann Neurol"},{"key":"612_CR23","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson\u2019s disease: MDS-PD Clinical Diagnostic Criteria. Mov Disord. 2015;30:1591\u2013601. https:\/\/doi.org\/10.1002\/mds.26424.","journal-title":"Mov Disord"},{"issue":"2","key":"612_CR24","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1212\/wnl.50.2.318","volume":"50","author":"MM Hoehn","year":"1998","unstructured":"Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology. 1998;50(2):427\u201342. https:\/\/doi.org\/10.1212\/wnl.50.2.318.","journal-title":"Neurology"},{"issue":"2","key":"612_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.47263\/JASEM.9(2)01","volume":"9","author":"MA Memon","year":"2025","unstructured":"Memon MA, Thurasamy R, Ting H, Cheah JH. Convenience sampling: a review and guidelines for quantitative research. J Appl Struct Equ Model. 2025;9(2):1\u201315. https:\/\/doi.org\/10.47263\/JASEM.9(2)01.","journal-title":"J Appl Struct Equ Model"},{"key":"612_CR26","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results: MDS-UPDRS: Clinimetric Assessment. Mov Disord. 2008;23:2129\u201370. https:\/\/doi.org\/10.1002\/mds.22340.","journal-title":"Mov Disord"},{"key":"612_CR27","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1002\/mds.29410","volume":"38","author":"ST Jost","year":"2023","unstructured":"Jost ST, Kaldenbach M, Antonini A, Martinez\u2010Martin P, Timmermann L, Odin P, et al. Levodopa dose equivalency in Parkinson\u2019s disease: updated systematic review and proposals. Mov Disord. 2023;38:1236\u201352. https:\/\/doi.org\/10.1002\/mds.29410.","journal-title":"Mov Disord"},{"key":"612_CR28","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.3233\/JPD-223170","volume":"12","author":"MHS Tosin","year":"2022","unstructured":"Tosin MHS, Simuni T, Stebbins GT, Cedarbaum JM. Tracking emergence of new motor and non-motor symptoms using the MDS-UPDRS: a novel outcome measure for early Parkinson\u2019s disease? J Parkinsons Dis. 2022;12:1345\u201351. https:\/\/doi.org\/10.3233\/JPD-223170.","journal-title":"J Parkinsons Dis"},{"key":"612_CR29","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/(SICI)1521-4036(200001)42:117::AID-BIMJ173.0.CO;2-U","volume":"42","author":"E Brunner","year":"2000","unstructured":"Brunner E, Munzel U. The nonparametric Behrens-Fisher problem: asymptotic theory and a small-sample approximation. Biom J. 2000;42:17\u201325. https:\/\/doi.org\/10.1002\/(SICI)1521-4036(200001)42:117::AID-BIMJ173.0.CO;2-U.","journal-title":"Biom J"},{"key":"612_CR30","doi-asserted-by":"crossref","unstructured":"Kleinman K, Huang SS. Calculating power by bootstrap, with an application to cluster-randomized trials. EGEMS (Wash DC). 2017;4(1):1202.","DOI":"10.13063\/2327-9214.1202"},{"key":"612_CR31","doi-asserted-by":"crossref","unstructured":"Saravanan V, Berman GJ, Sober SJ. Application of the hierarchical bootstrap to multi-level data in neuroscience. Neuron Behav Data Anal Theory. 2020;3(5):1\u201325","DOI":"10.1101\/819334"},{"key":"612_CR32","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1001\/archopht.1966.03850010164003","volume":"76","author":"GK Von Noorden","year":"1966","unstructured":"Von Noorden GK, Preziosi TJ. Eye movement recordings in neurological disorders. Arch Ophthalmol. 1966;76:162\u201371. https:\/\/doi.org\/10.1001\/archopht.1966.03850010164003.","journal-title":"Arch Ophthalmol"},{"key":"612_CR33","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1093\/brain\/112.5.1193","volume":"112","author":"O Rascol","year":"1989","unstructured":"Rascol O, Clanet M, Montastruc JL, Simonetta M, Soulier-Esteve MJ, Doyon B, et al. Abnormal ocular movements in Parkinson\u2019s disease: evidence for involvement of dopaminergic systems. Brain. 1989;112:1193\u2013214. https:\/\/doi.org\/10.1093\/brain\/112.5.1193.","journal-title":"Brain"},{"key":"612_CR34","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.clinph.2013.01.021","volume":"124","author":"Y Terao","year":"2013","unstructured":"Terao Y, Fukuda H, Ugawa Y, Hikosaka O. New perspectives on the pathophysiology of Parkinson\u2019s disease as assessed by saccade performance: a clinical review. Clin Neurophysiol. 2013;124:1491\u2013506. https:\/\/doi.org\/10.1016\/j.clinph.2013.01.021.","journal-title":"Clin Neurophysiol"},{"issue":"Pt 3","key":"612_CR35","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1093\/brain\/106.3.571","volume":"106","author":"OB White","year":"1983","unstructured":"White OB, Saint-Cyr JA, Tomlinson RD, Sharpe JA. Ocular motor deficits in Parkinson\u2019s disease. II. Control of the saccadic and smooth pursuit systems. Brain. 1983;106(Pt 3):571\u201387. https:\/\/doi.org\/10.1093\/brain\/106.3.571.","journal-title":"Brain"},{"key":"612_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2024.107951","author":"D Li","year":"2024","unstructured":"Li D, Butala AA, Moro-Velazquez L, Meyer T, Oh ES, Motley C, et al. Automating the analysis of eye movement for different neurodegenerative disorders. Comput Biol Med. 2024. https:\/\/doi.org\/10.1016\/j.compbiomed.2024.107951.","journal-title":"Comput Biol Med"},{"key":"612_CR37","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.jocn.2011.10.014","volume":"19","author":"S Van Stockum","year":"2012","unstructured":"Van Stockum S, MacAskill MR, Anderson TJ. Impairment of voluntary saccades and facilitation of reflexive saccades do not co-occur in Parkinson\u2019s disease. J Clin Neurosci. 2012;19:1119\u201324. https:\/\/doi.org\/10.1016\/j.jocn.2011.10.014.","journal-title":"J Clin Neurosci"},{"key":"612_CR38","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/eye.2014.276","volume":"29","author":"CA Antoniades","year":"2015","unstructured":"Antoniades CA, Kennard C. Ocular motor abnormalities in neurodegenerative disorders. Eye. 2015;29:200\u20137. https:\/\/doi.org\/10.1038\/eye.2014.276.","journal-title":"Eye"},{"key":"612_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-019-0083-7","volume":"5","author":"J Waldthaler","year":"2019","unstructured":"Waldthaler J, Tsitsi P, Svenningsson P. Vertical saccades and antisaccades: complementary markers for motor and cognitive impairment in Parkinson\u2019s disease. npj Parkinsons Dis. 2019;5:11. https:\/\/doi.org\/10.1038\/s41531-019-0083-7.","journal-title":"npj Parkinsons Dis"},{"key":"612_CR40","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/mdc3.12553","volume":"5","author":"SK Holden","year":"2018","unstructured":"Holden SK, Finseth T, Sillau SH, Berman BD. Progression of MDS-UPDRS scores over five years in de novo Parkinson disease from the Parkinson\u2019s Progression Markers Initiative cohort. Mov Disord Clin Pract. 2018;5:47\u201353. https:\/\/doi.org\/10.1002\/mdc3.12553.","journal-title":"Mov Disord Clin Pract"},{"key":"612_CR41","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/j.parkreldis.2017.07.029","volume":"46","author":"S-Y Lim","year":"2018","unstructured":"Lim S-Y, Tan AH. Historical perspective: the pros and cons of conventional outcome measures in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2018;46:S47-52. https:\/\/doi.org\/10.1016\/j.parkreldis.2017.07.029.","journal-title":"Parkinsonism Relat Disord"},{"key":"612_CR42","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1123\/jab.2013-0319","volume":"31","author":"V Robles-Garc\u00eda","year":"2015","unstructured":"Robles-Garc\u00eda V, Corral-Berganti\u00f1os Y, Espinosa N, J\u00e1come MA, Garc\u00eda-Sancho C, Cudeiro J, et al. Spatiotemporal gait patterns during overt and covert evaluation in patients with Parkinson\u2019s disease and healthy subjects: is there a Hawthorne Effect? J Appl Biomech. 2015;31:189\u201394. https:\/\/doi.org\/10.1123\/jab.2013-0319.","journal-title":"J Appl Biomech"},{"key":"612_CR43","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1007\/s00415-019-09348-3","volume":"266","author":"A Regnault","year":"2019","unstructured":"Regnault A, Boroojerdi B, Meunier J, Bani M, Morel T, Cano S. Does the MDS-UPDRS provide the precision to assess progression in early Parkinson\u2019s disease? Learnings from the Parkinson\u2019s Progression Marker Initiative cohort. J Neurol. 2019;266:1927\u201336. https:\/\/doi.org\/10.1007\/s00415-019-09348-3.","journal-title":"J Neurol"},{"key":"612_CR44","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1002\/mds.27790","volume":"34","author":"LJW Evers","year":"2019","unstructured":"Evers LJW, Krijthe JH, Meinders MJ, Bloem BR, Heskes TM. Measuring Parkinson\u2019s disease over time: the real\u2010world within\u2010subject reliability of the MDS\u2010UPDRS. Mov Disord. 2019;34:1480\u20137. https:\/\/doi.org\/10.1002\/mds.27790.","journal-title":"Mov Disord"},{"key":"612_CR45","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/mds.24997","volume":"28","author":"AE Lang","year":"2013","unstructured":"Lang AE, Melamed E, Poewe W, Rascol O. Trial designs used to study neuroprotective therapy in Parkinson\u2019s disease. Mov Disord. 2013;28:86\u201395. https:\/\/doi.org\/10.1002\/mds.24997.","journal-title":"Mov Disord"},{"key":"612_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.prdoa.2024.100278","volume":"11","author":"L Kenny","year":"2024","unstructured":"Kenny L, Azizi Z, Moore K, Alcock M, Heywood S, Jonsson A, et al. Inter-rater reliability of hand motor function assessment in Parkinson\u2019s disease: Impact of clinician training. Clin Parkinsonism Related Disord. 2024;11:100278. https:\/\/doi.org\/10.1016\/j.prdoa.2024.100278.","journal-title":"Clin Parkinsonism Related Disord"},{"key":"612_CR47","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1002\/mds.22645","volume":"24","author":"P Huang","year":"2009","unstructured":"Huang P, Goetz CG, Woolson RF, Tilley B, Kerr D, Palesch Y, et al. Using global statistical tests in long\u2010term Parkinson\u2019s disease clinical trials. Mov Disord. 2009;24:1732\u20139. https:\/\/doi.org\/10.1002\/mds.22645.","journal-title":"Mov Disord"},{"key":"612_CR48","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.3233\/JPD-230446","volume":"14","author":"B Ribba","year":"2024","unstructured":"Ribba B, Simuni T, Marek K, Siderowf A, Diack C, Pierrillas PB, et al. Modeling of Parkinson\u2019s disease progression and implications for detection of disease modification in treatment trials. J Parkinsons Dis. 2024;14:1225\u201335. https:\/\/doi.org\/10.3233\/JPD-230446.","journal-title":"J Parkinsons Dis"},{"key":"612_CR49","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1001\/jama.2019.22360","volume":"323","author":"MJ Armstrong","year":"2020","unstructured":"Armstrong MJ, Okun MS. Diagnosis and treatment of Parkinson disease: a review. JAMA. 2020;323:548. https:\/\/doi.org\/10.1001\/jama.2019.22360.","journal-title":"JAMA"},{"key":"612_CR50","doi-asserted-by":"publisher","DOI":"10.1002\/mds.30259","author":"MM Mouradian","year":"2025","unstructured":"Mouradian MM, Stoessl AJ, Lang AE. Disease\u2010modifying trials in treated Parkinson\u2019s disease: \u201cStable Treated\u201d does not equate with biological stability. Mov Disord. 2025. https:\/\/doi.org\/10.1002\/mds.30259.","journal-title":"Mov Disord"},{"key":"612_CR51","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/mds.25337","volume":"28","author":"F Stocchi","year":"2013","unstructured":"Stocchi F, Olanow CW. Obstacles to the development of a neuroprotective therapy for Parkinson\u2019s disease. Mov Disord. 2013;28:3\u20137. https:\/\/doi.org\/10.1002\/mds.25337.","journal-title":"Mov Disord"},{"key":"612_CR52","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/s0140-6736(17)31585-4","volume":"390","author":"D Athauda","year":"2017","unstructured":"Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K, et al. Exenatide once weekly versus placebo in Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390:1664\u201375. https:\/\/doi.org\/10.1016\/s0140-6736(17)31585-4.","journal-title":"Lancet"},{"key":"612_CR53","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.parkreldis.2019.09.029","volume":"68","author":"Z Lu","year":"2019","unstructured":"Lu Z, Buchanan T, Kennard C, FitzGerald JJ, Antoniades CA. The effect of levodopa on saccades\u2014Oxford quantification in parkinsonism study. Parkinsonism Relat Disord. 2019;68:49\u201356. https:\/\/doi.org\/10.1016\/j.parkreldis.2019.09.029.","journal-title":"Parkinsonism Relat Disord"},{"key":"612_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinph.2022.07.505","author":"MJ Munoz","year":"2022","unstructured":"Munoz MJ, Reilly JL, Pal GD, Verhagen Metman L, Rivera YM, Drane QH, et al. Medication adversely impacts visually-guided eye movements in Parkinson\u2019s disease. Clin Neurophysiol. 2022. https:\/\/doi.org\/10.1016\/j.clinph.2022.07.505.","journal-title":"Clin Neurophysiol"},{"key":"612_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-019-0107-3","volume":"6","author":"EA Pelzer","year":"2020","unstructured":"Pelzer EA, Dillenburger B, Grundmann S, Iliaev V, Aschenberg S, Melzer C, et al. Hypomania and saccadic changes in Parkinson\u2019s disease: influence of D2 and D3 dopaminergic signalling. npj Parkinsons Dis. 2020;6:5. https:\/\/doi.org\/10.1038\/s41531-019-0107-3.","journal-title":"npj Parkinsons Dis"},{"key":"612_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.bionps.2023.100074","volume":"9","author":"KY Yamashita","year":"2023","unstructured":"Yamashita KY, Bhoopatiraju S, Silverglate BD, Grossberg GT. Biomarkers in Parkinson\u2019s disease: a state of the art review. Biomark Neuropsychiatry. 2023;9:100074. https:\/\/doi.org\/10.1016\/j.bionps.2023.100074.","journal-title":"Biomark Neuropsychiatry"},{"key":"612_CR57","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.1312","volume":"78","author":"T Mitchell","year":"2021","unstructured":"Mitchell T, Leh\u00e9ricy S, Chiu SY, Strafella AP, Stoessl AJ, Vaillancourt DE. Emerging neuroimaging biomarkers across disease stage in Parkinson disease: a review. JAMA Neurol. 2021;78:1262. https:\/\/doi.org\/10.1001\/jamaneurol.2021.1312.","journal-title":"JAMA Neurol"},{"key":"612_CR58","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/s1474-4422(23)00404-0","volume":"23","author":"GU H\u00f6glinger","year":"2024","unstructured":"H\u00f6glinger GU, Adler CH, Berg D, Klein C, Outeiro TF, Poewe W, et al. A biological classification of Parkinson\u2019s disease: The SynNeurGe research diagnostic criteria. Lancet Neurol. 2024;23:191\u2013204. https:\/\/doi.org\/10.1016\/s1474-4422(23)00404-0. (Elsevier BV).","journal-title":"Lancet Neurol"},{"key":"612_CR59","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/s1474-4422(23)00405-2","volume":"23","author":"T Simuni","year":"2024","unstructured":"Simuni T, Chahine LM, Poston K, Brumm M, Buracchio T, Campbell M, et al. A biological definition of neuronal \u03b1-synuclein disease: Towards an integrated staging system for research. Lancet Neurol. 2024;23:178\u201390. https:\/\/doi.org\/10.1016\/s1474-4422(23)00405-2.","journal-title":"Lancet Neurol"},{"key":"612_CR60","doi-asserted-by":"publisher","DOI":"10.3389\/fdgth.2024.1472691","volume":"6","author":"S Hirczy","year":"2024","unstructured":"Hirczy S, Zabetian C, Lin Y-H. The current state of wearable device use in Parkinson\u2019s disease: A survey of individuals with Parkinson\u2019s. Front Digit Health. 2024;6:1472691. https:\/\/doi.org\/10.3389\/fdgth.2024.1472691.","journal-title":"Front Digit Health"},{"key":"612_CR61","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.ncl.2024.12.009","volume":"43","author":"M Fabbri","year":"2025","unstructured":"Fabbri M, Corvol JC, Rascol O. Disease-modifying therapies in Parkinson\u2019s Disease. Neurol Clin. 2025;43:319\u201340. https:\/\/doi.org\/10.1016\/j.ncl.2024.12.009.","journal-title":"Neurol Clin"},{"key":"612_CR62","doi-asserted-by":"publisher","first-page":"899","DOI":"10.3233\/JPD-240272","volume":"14","author":"K McFarthing","year":"2024","unstructured":"McFarthing K, Buff S, Rafaloff G, Pitzer K, Fiske B, Navangul A, et al. Parkinson\u2019s Disease drug therapies in the clinical trial pipeline: 2024 update. J Parkinsons Dis. 2024;14:899\u2013912. https:\/\/doi.org\/10.3233\/JPD-240272.","journal-title":"J Parkinsons Dis"}],"container-title":["Pharmaceutical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-026-00612-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40290-026-00612-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-026-00612-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T15:04:42Z","timestamp":1783177482000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40290-026-00612-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,30]]},"references-count":62,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["612"],"URL":"https:\/\/doi.org\/10.1007\/s40290-026-00612-2","relation":{},"ISSN":["1178-2595","1179-1993"],"issn-type":[{"value":"1178-2595","type":"print"},{"value":"1179-1993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,30]]},"assertion":[{"value":"5 May 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MHST, PM, TG, RNA, and CGG declare no conflict of interests. OR is the head of the scientific advisory board at NeuraLight LTD. ER, IR, EH, TB\u00a0and EBA are all employees of NeuraLight. TG reports consultancy fees from AbbVie, Medison, and Teva; a travel support from Alphamedix, AbbVie, Cytora, and Medison; honoraria for lectures from AbbVie and Medison; and grants from the International Parkinson Disease and Movement Disorders Society, the Parkinson\u2019s Foundation, and Mission MSA. OR has participated in advisory boards and\/or provided consultancy or lectures for Apopharma, AstraZeneca, Bial, Biogen, Britannia, Cerevel, Contera, GE Healthcare, Ionis, LGD Nuvamid, Lundbeck, Merz, NeuraLight, Neuroderm, ONO Pharma, Orion Pharma, PD Neurotechnology, Roche Therapeutics, Sanofi, Servier, Sunovion, Supernus, Thelonius Mind, Takeda, Teva, UCB, and Zambon and has received grants from Agence Nationale de la Recherche (ANR), CHU de Toulouse, France-Parkinson, MJFox Foundation, French Ministry of Health (Programme Hospitalier de Recherche Clinique), European Commission (H2020 & Horizon Europe), and Cure Parkinson\u2019s. CGG had research funding, provided to Rush University Medical Center, from NIH, UO1 funding from NIDDK, and grants from the Department of Defense and Michael J. Fox Foundation. He had honoraria regarding a faculty stipend and Program Management stipend from the International Parkinson and Movement Disorder Society. He has royalties from Elsevier Publishers, Wolters Kluwer, Oxford University Press, and Springer Science. He receives salary from Rush University Medical Center. MHST had research funding to Rush University Medical Center from the International Parkinson and Movement Disorder Society. She receives a salary from Rush University Medical Center. RNA had research funding from the Michael J. Fox Foundation, the Silverstein Foundation, the Parkinson\u2019s Foundation, and the Aufzien Family Center for the Prevention and Treatment of Parkinson's Disease. He received consultation fees from Bexxion, Biogen, Biohaven, Capsida, Gain Therapeutics, Genzyme\/Sanofi, Janssen, SK Biopharmaceuticals, Takeda, and Vanqua Bio. PM has received financial support from the Spanish Ministry of Science and Innovation (RTC2019-007150-1), the Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (ISCIII-FEDER) (PI16\/01575, PI18\/01898, PI19\/01576, PI20\/00613, PI21\/01875, PI22\/01704, PI23\/00512), the Consejer\u00eda de Econom\u00eda, Innovaci\u00f3n, Ciencia y Empleo de la Junta de Andaluc\u00eda (CVI-02526, CTS-7685), the Consejer\u00eda de Salud y Bienestar Social de la Junta de Andaluc\u00eda (PI-0471-2013, PE-0210-2018, PI-0459-2018, PE-0186-2019), the Consejer\u00eda de Transformaci\u00f3n Econ\u00f3mica, Industria, Conocimiento y Universidades de la Junta de Andaluc\u00eda (PY20_00896). PM has also received support for attending meetings and\/or travel or honorarium for lecturing from Abbott, Allergan, AbbVie, Bial, Britannia, Italfarmaco, Merz, UCB, Teva, and Zambon.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Data supporting the findings in the present study are reported in the article. The raw data collected and analyzed are available from the corresponding author on reasonable request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Both trials were approved by the local ethics committees.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Informed consent was obtained from each patient.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Writing of manuscript: ER, EBA, and OR. Design and conceptualization of trials: EBA, ER, and OR. Trial execution: MHST, PM, and TG. Trial supervision: RNA and CGG. Data analysis: EH, IR, TB, and EBA. Preparation of figures: IR and EH. Reading and approving the manuscript: All authors.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}